Literature DB >> 19182515

Paths of FGFR-driven tumorigenesis.

Victor D Acevedo1, Michael Ittmann, David M Spencer.   

Abstract

Fibroblast growth factor receptors (FGFRs) comprise a subfamily of receptor tyrosine kinases (RTKs) that are master regulators of a broad spectrum of cellular and developmental processes, including apoptosis, proliferation, migration and angiogenesis. Due to their broad impact, FGFRs and other RTKs are highly regulated and normally only basally active. Deregulation of FGFR signaling by activating mutations or ligand/receptor overexpression could allow these receptors to become constitutively active, leading to cancer development, including both hematopoietic and solid tumors, such as breast, bladder and prostate carcinomas. In this review, we focus on potential modes of FGFR-mediated tumorigenesis, in particular, the role of FGFR1 during prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182515     DOI: 10.4161/cc.8.4.7657

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  58 in total

Review 1.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

2.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

3.  Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.

Authors:  Sanaz Memarzadeh; Houjian Cai; Deanna M Janzen; Li Xin; Rita Lukacs; Mireille Riedinger; Yang Zong; Karel DeGendt; Guido Verhoeven; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 4.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 5.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

6.  A molecular signature predictive of indolent prostate cancer.

Authors:  Shazia Irshad; Mukesh Bansal; Mireia Castillo-Martin; Tian Zheng; Alvaro Aytes; Sven Wenske; Clémentine Le Magnen; Paolo Guarnieri; Pavel Sumazin; Mitchell C Benson; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Sci Transl Med       Date:  2013-09-11       Impact factor: 17.956

Review 7.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

8.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

9.  Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.

Authors:  Christine Spiegelberg; Johannes Giedl; Nadine T Gaisa; Anja Rogler; Marc-Oliver Riener; Thomas Filbeck; Maximilian Burger; Petra Ruemmele; Arndt Hartmann; Robert Stoehr
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis.

Authors:  Zhuo Chen; Lin-Jiang Tong; Bai-You Tang; Hong-Yan Liu; Xin Wang; Tao Zhang; Xian-Wen Cao; Yi Chen; Hong-Lin Li; Xu-Hong Qian; Yu-Fang Xu; Hua Xie; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2018-11-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.